Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning for Stem Cell Transplantation.

被引：0
|
作者：
Bremer, S. [1 ]
Floeisand, Y. [2 ]
Bergan, S. [3 ,4 ]
机构：
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Oslo Univ Hosp, Dept Hematol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Pharmacol, Oslo, Norway
[4] Univ Oslo, Sch Pharm, Oslo, Norway
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-03003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A30
引用
收藏
页码：880 / 880
页数：1
相关论文
共 50 条
  • [31] Better Outcome of Patients Undergoing Enteral Tube Feeding After Myeloablative Conditioning for Allogeneic Stem Cell Transplantation
    Seguy, David
    Duhamel, Alain
    Ben Rejeb, Majd
    Gomez, Emmanuel
    Buhl, Nicolas Danel
    Bruno, Benedicte
    Cortot, Antoine
    Yakoub-Agha, Ibrahim
    TRANSPLANTATION, 2012, 94 (03) : 287 - 294
  • [32] Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation
    US Schuler
    M Ehrsam
    A Schneider
    H Schmidt
    J Deeg
    G Ehninger
    Bone Marrow Transplantation, 1998, 22 : 241 - 244
  • [33] Pharmacokinetics of treosulfan in a myeloablative conditioning combination with cyclophosphamide prior to allogeneic haematopoietic stem cell transplantation
    Hilger, RA
    Scheulen, ME
    Trenschel, R
    Seeber, S
    Beelen, DW
    BONE MARROW TRANSPLANTATION, 2004, 33 : S173 - S174
  • [34] Non-myeloablative regimen consisting of busulfan, fludarabine, and ATG for allogeneic peripheral blood stem cell transplantation.
    Mayer, J
    Koristek, Z
    Krahulová, M
    Vorlicek, J
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 131 - 131
  • [35] Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation
    Schuler, US
    Ehrsam, M
    Schneider, A
    Schmidt, H
    Deeg, J
    Ehninger, G
    BONE MARROW TRANSPLANTATION, 1998, 22 (03) : 241 - 244
  • [36] Busulfan-fludarabine as myeloablative conditioning regimen in allogeneic stem cell transplantation: incidence of complications and outcome. A single-centre experience
    Parma, M.
    Pioltelli, P.
    Terruzzi, E.
    Bozzani, S.
    Pogliani, E.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S94 - S94
  • [37] New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
    Sohn, S. K.
    Chae, Y. S.
    Kim, J. G.
    Cho, Y. Y.
    Moon, J. H.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Yang, D. H.
    Lee, J. J.
    Kim, Y. K.
    Kim, H. J.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S203 - S204
  • [38] MYELOABLATIVE DOSES OF BUSULFAN AND FLUDARABINE AS CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA
    Figueroa, J.
    Perkins, J.
    Anassetti, C.
    Tomblyn, M.
    Field, T.
    Fernandez, H.
    Ochoa, J.
    Perez, L.
    Alsina, M.
    Locke, F.
    Nishihori, T.
    Pidala, J.
    Ayala, E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S297 - S297
  • [39] New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
    Chae, Y. S.
    Sohn, S. K.
    Kim, J. G.
    Cho, Y. Y.
    Moon, J. H.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Yang, D. H.
    Lee, J-J
    Kim, Y-K
    Kim, H-J
    BONE MARROW TRANSPLANTATION, 2007, 40 (06) : 541 - 547
  • [40] New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
    Y S Chae
    S K Sohn
    J G Kim
    Y Y Cho
    J H Moon
    H J Shin
    J S Chung
    G J Cho
    D H Yang
    J-J Lee
    Y-K Kim
    H-J Kim
    Bone Marrow Transplantation, 2007, 40 : 541 - 547
12345